

Christopher R Cogle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/201960/publications.pdf>

Version: 2024-02-01

215
papers

6,282
citations

94433
37
h-index

76900
74
g-index

216
all docs

216
docs citations

216
times ranked

8750
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	27.8	907
2	Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1717-26.	7.4	424
3	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2110.	7.4	377
4	Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2380-9.	7.4	357
5	Bone marrow transdifferentiation in brain after transplantation: a retrospective study. <i>Lancet</i> , The, 2004, 363, 1432-1437.	13.7	298
6	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2521-2527.	1.6	232
7	Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. <i>Blood</i> , 2011, 117, 7121-7125.	1.4	191
8	Aldehyde dehydrogenase activity as a functional marker for lung cancer. <i>Chemico-Biological Interactions</i> , 2009, 178, 48-55.	4.0	155
9	Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. <i>Blood</i> , 2005, 106, 95-102.	1.4	118
10	HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. <i>Cancer Cell</i> , 2019, 36, 645-659.e8.	16.8	116
11	Incidence and Burden of the Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 272-281.	2.3	108
12	Bone Marrow Contributes to Epithelial Cancers in Mice and Humans as Developmental Mimicry. <i>Stem Cells</i> , 2007, 25, 1881-1887.	3.2	83
13	Leukemia regression by vascular disruption and antiangiogenic therapy. <i>Blood</i> , 2010, 116, 1539-1547.	1.4	81
14	Functional integration of acute myeloid leukemia into the vascular niche. <i>Leukemia</i> , 2014, 28, 1978-1987.	7.2	75
15	Adult human hematopoietic cells provide functional hemangioblast activity. <i>Blood</i> , 2004, 103, 133-135.	1.4	74
16	Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. <i>American Heart Journal</i> , 2009, 158, 356-363.	2.7	74
17	PARP1 is required for chromosomal translocations. <i>Blood</i> , 2013, 121, 4359-4365.	1.4	67
18	Underreporting of Myeloid Malignancies by United States Cancer Registries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 474-481.	2.5	66

#	ARTICLE	IF	CITATIONS
19	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. <i>Circulation Research</i> , 2014, 115, 867-874.	4.5	65
20	Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. <i>Circulation Research</i> , 2015, 116, 99-107.	4.5	65
21	Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar. <i>Healthcare (Switzerland)</i> , 2021, 9, 351.	2.0	62
22	Bone marrow niche in the myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 1020-1027.	0.8	61
23	Bone marrow stem and progenitor cell contribution to neovasclogenesis is dependent on model system with SDF-1 as a permissive trigger. <i>Blood</i> , 2009, 114, 4310-4319.	1.4	60
24	Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl. <i>Blood</i> , 2014, 124, 1232-1241.	1.4	59
25	Selective Purging of Human Multiple Myeloma Cells from Autologous Stem Cell Transplantation Grafts using Oncolytic Myxoma Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1540-1551.	2.0	56
26	CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. <i>Blood</i> , 2018, 132, 837-848.	1.4	56
27	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2015, 10, e0135520.	2.5	54
28	Acute myeloid leukemia in the vascular niche. <i>Cancer Letters</i> , 2016, 380, 552-560.	7.2	53
29	An Overview of Stem Cell Research and Regulatory Issues. <i>Mayo Clinic Proceedings</i> , 2003, 78, 993-1003.	3.0	51
30	Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells. <i>Hypertension</i> , 2016, 67, 574-584.	2.7	50
31	LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. <i>Texas Heart Institute Journal</i> , 2010, 37, 412-20.	0.3	50
32	HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia. <i>Molecular Cell</i> , 2022, 82, 833-851.e11.	9.7	48
33	Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	1.3	47
34	Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. <i>Leukemia</i> , 2009, 23, 2313-2317.	7.2	43
35	Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US) <i>Tj ETQq1 1 0.7824314 rg8740</i>	0.7824314	41
36	Developmental Differences in Megakaryocyte Maturation Are Determined by the Microenvironment. <i>Stem Cells</i> , 2005, 23, 1400-1408.	3.2	41

#	ARTICLE	IF	CITATIONS
37	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.8	41
38	Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 84, 106180.	0.8	41
39	The hemangioblast: Cradle to clinic. <i>Experimental Hematology</i> , 2004, 32, 885-890.	0.4	39
40	Bone Marrow-Derived Stem-Cell Repopulation Contributes Minimally to the Type II Pneumocyte Pool in Transplanted Human Lungs. <i>Transplantation</i> , 2005, 80, 206-212.	1.0	37
41	The hunt for cancer-initiating cells: a history stemming from leukemia. <i>Leukemia</i> , 2007, 21, 1619-1627.	7.2	37
42	Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2018, 33, 29-37.	1.3	36
43	The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. <i>Journal of Translational Medicine</i> , 2006, 4, 9.	4.4	35
44	Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. <i>Cytotherapy</i> , 2010, 12, 684-691.	0.7	33
45	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction. <i>Circulation Research</i> , 2017, 120, 1947-1957.	4.5	33
46	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Oncologist</i> , 2015, 20, 1404-1412.	3.7	32
47	Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. <i>Cell Transplantation</i> , 2016, 25, 1675-1687.	2.5	32
48	An Overview of Stem Cell Research and Regulatory Issues. <i>Mayo Clinic Proceedings</i> , 2003, 78, 993-1003.	3.0	31
49	Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 169-175.	7.2	31
50	Oncolytic Virotherapy for Hematological Malignancies. <i>Advances in Virology</i> , 2012, 2012, 1-8.	1.1	31
51	An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats. <i>International Journal of Cardiology</i> , 2016, 220, 149-154.	1.7	31
52	High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. <i>Leukemia Research</i> , 2014, 38, 71-75.	0.8	30
53	Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. <i>Blood</i> , 2015, 125, 3778-3788.	1.4	29
54	Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. <i>Molecular Therapy - Oncolytics</i> , 2017, 4, 31-40.	4.4	27

#	ARTICLE	IF	CITATIONS
55	Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology, 2003, 73, 169-175.	4.1	24
56	Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clinical Advances in Hematology and Oncology, 2010, 8, 40-6.	0.3	23
57	Chemosensitizing AML cells by targeting bone marrow endothelial cells. Experimental Hematology, 2016, 44, 363-377.e5.	0.4	22
58	Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. Cytotherapy, 2016, 18, 465-480.	0.7	21
59	Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 634.	6.2	21
60	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers, 2020, 12, 74.	3.7	21
61	Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts. Journal of Leukocyte Biology, 2007, 81, 632-641.	3.3	20
62	Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leukemia Research, 2012, 36, 619-624.	0.8	20
63	Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition. Leukemia Research, 2015, 39, 984-989.	0.8	20
64	CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research, 2018, 72, 79-85.	0.8	20
65	A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers, 2021, 13, 4113.	3.7	20
66	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRn) trial. American Heart Journal, 2016, 179, 142-150.	2.7	18
67	Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. American Heart Journal, 2011, 162, 973-980.	2.7	17
68	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leukemia Research Reports, 2015, 4, 24-27.	0.4	17
69	Characteristics of thawed autologous umbilical cord blood. Transfusion, 2012, 52, 2234-2242.	1.6	16
70	The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. Oncologist, 2017, 22, 379-385.	3.7	16
71	Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?. International Journal of Environmental Research and Public Health, 2019, 16, 1076.	2.6	16
72	Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research, 2019, 77, 42-50.	0.8	16

#	ARTICLE	IF	CITATIONS
73	The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-mediated Human Pathological Cell Growth in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2011, 286, 4280-4291.	3.4	15
74	Clinical Application of Computational Methods in Precision Oncology. <i>JAMA Oncology</i> , 2020, 6, 1282.	7.1	15
75	Donor-derived type II pneumocytes are rare in the lungs of allogeneic hematopoietic cell transplant recipients. <i>Annals of Clinical and Laboratory Science</i> , 2006, 36, 47-52.	0.2	15
76	Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells. <i>PLoS ONE</i> , 2012, 7, e43298.	2.5	14
77	Effect of melphalan 140Âmg/m ² vs 200Âmg/m ² on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantationâ€”a single center experience. <i>Clinical Transplantation</i> , 2016, 30, 894-900.	1.6	14
78	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. <i>Leukemia Research</i> , 2017, 52, 1-7.	0.8	14
79	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 424-424.	1.4	14
80	Association of breast carcinoma growth with a non-canonical axis of IFN ^{Î³} /IDO1/TSP1. <i>Oncotarget</i> , 2017, 8, 85024-85039.	1.8	14
81	Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR]) Tj ETQq1 1 0z784314 rgsT /Over	1.7	14
82	Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System. <i>Healthcare (Switzerland)</i> , 2022, 10, 264.	2.0	13
83	A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. <i>Leukemia Research</i> , 2016, 46, 69-73.	0.8	12
84	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. <i>BMC Cancer</i> , 2016, 16, 652.	2.6	12
85	Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. <i>Journal of Clinical Oncology</i> , 2019, 37, 1690-1694.	1.6	12
86	The Jak2 Inhibitor, G6, Alleviates Jak2-V617Fâ€”Mediated Myeloproliferative Neoplasia by Providing Significant Therapeutic Efficacy to the Bone Marrow. <i>Neoplasia</i> , 2011, 13, 1058-1068.	5.3	11
87	Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 1453-1456.	0.8	11
88	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation â€” Coronary Vascular Dysfunction Study (WISE-CVD). <i>Atherosclerosis</i> , 2016, 253, 111-117.	0.8	11
89	Exploring the Structureâ€”Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6892-6903.	6.4	11
90	Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics. <i>Leukemia Research</i> , 2019, 78, 3-11.	0.8	11

#	ARTICLE	IF	CITATIONS
91	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. <i>Blood Advances</i> , 2019, 3, 1837-1847.	5.2	10
92	Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. <i>Blood</i> , 2010, 116, 603-603.	1.4	10
93	A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1463-1463.	1.4	10
94	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2018, 24, 4098-4109.	7.0	9
95	Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 23-31.	0.9	9
96	Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020, 189, e211-e213.	2.5	9
97	The Hematopoietic Stem Cell Is a Source of Endothelial Cells in Cancer Vasculogenesis and Depends on SDF-1. <i>Blood</i> , 2007, 110, 3722-3722.	1.4	9
98	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. <i>Clinical Cancer Research</i> , 2022, 28, 756-769.	7.0	9
99	Marrow cell therapies for cardiovascular diseases. <i>Experimental Hematology</i> , 2008, 36, 687-694.	0.4	8
100	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. <i>Current Atherosclerosis Reports</i> , 2013, 15, 341.	4.8	8
101	Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. <i>Viruses</i> , 2016, 8, 85.	3.3	8
102	Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. <i>Leukemia Research</i> , 2017, 60, 123-128.	0.8	8
103	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. <i>Blood</i> , 2016, 128, 905-905.	1.4	8
104	The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis. <i>American Journal of Pathology</i> , 2012, 181, 858-865.	3.8	7
105	Clinical significance of <i>in vivo</i> cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016, 57, 909-920.	1.3	7
106	Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2. <i>Leukemia Research</i> , 2017, 61, 104-107.	0.8	7
107	Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 478-483.	2.3	7
108	Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults. <i>Frontiers in Immunology</i> , 2020, 11, 1289.	4.8	7

#	ARTICLE	IF	CITATIONS
109	Building a precision oncology workforce by multidisciplinary and case-based learning. BMC Medical Education, 2021, 21, 75.	2.4	7
110	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of Clinical Oncology, 2022, 40, 772-783.	1.6	7
111	Stem cell research. Paediatric Respiratory Reviews, 2006, 7, 135-140.	1.8	6
112	Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. Biochemical and Biophysical Research Communications, 2015, 462, 283-287.	2.1	6
113	CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation. Leukemia Research, 2018, 74, 110-112.	0.8	6
114	Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia. Cancers, 2020, 12, 3710.	3.7	6
115	Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. Blood, 2012, 120, 1337-1337.	1.4	6
116	Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study. Transfusion, 2012, 52, 2225-2233.	1.6	5
117	Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2. Journal of the National Cancer Institute, 2013, 105, 378-379.	6.3	5
118	Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplantâ€”A Prospective Phase II Study. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S16835.	1.3	5
119	Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians. Transfusion, 2015, 55, 1766-1771.	1.6	5
120	Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 251-254.	0.4	5
121	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectÂ®MDS/AML Disease Registry. EJHaem, 2020, 1, 58-68.	1.0	5
122	Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. Future Oncology, 2021, 17, 263-277.	2.4	5
123	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).. Blood, 2009, 114, 117-117.	1.4	5
124	Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells.. Blood, 2009, 114, 14-14.	1.4	5
125	A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy. Blood, 2015, 126, 1352-1352.	1.4	5
126	Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS. Blood, 2016, 128, 594-594.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Early Treatment Initiation in Myelodysplastic Syndromes (MDS) Produces Higher Rate of and Earlier Transfusion Independence. <i>Blood</i> , 2016, 128, 395-395.	1.4	5
128	Costâ€ effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 275-284.	1.4	4
129	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. <i>Leukemia Research</i> , 2019, 81, 43-49.	0.8	4
130	Bone Marrow Endothelial Cells Protect Acute Myeloid Leukemia From Chemotherapy By Direct Contact: The BCAM/Laminin/VLA5 Axis As a Potential Therapeutic Target. <i>Blood</i> , 2013, 122, 2546-2546.	1.4	4
131	Personalized Therapy Design for MPN Using Predictive Simulation Methodology with in Vitro, Ex Vivo, and in Vivo Validatio. <i>Blood</i> , 2014, 124, 3212-3212.	1.4	4
132	The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS. <i>Blood</i> , 2015, 126, 4936-4936.	1.4	4
133	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECTA® Myelodysplastic Syndromes (MDS) and AML Disease Registry. <i>Blood</i> , 2016, 128, 3548-3548.	1.4	4
134	Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples. <i>Blood</i> , 2016, 128, 5206-5206.	1.4	4
135	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. <i>Cancers</i> , 2021, 13, 5287.	3.7	4
136	Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3323.	4.1	3
137	Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.. <i>Blood</i> , 2010, 116, 1057-1057.	1.4	3
138	Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2011, 118, 1546-1546.	1.4	3
139	Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies. <i>Blood</i> , 2014, 124, 2598-2598.	1.4	3
140	Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy. <i>Blood</i> , 2014, 124, 2627-2627.	1.4	3
141	Radiation Alone for Solid Tumors and the Questionable Development of Therapy-Related Myelodysplastic Syndromes. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju025-dju025.	6.3	2
142	Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the ConnectA® MDS/AML Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S98-S99.	2.0	2
143	Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care. <i>Healthcare (Switzerland)</i> , 2020, 8, 214.	2.0	2
144	Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1554-1554.	1.4	2

#	ARTICLE	IF	CITATIONS
145	A Genomic Rule Predicting HMA Treatment Response in MDS Identified By Protein Network Mapping and Validated By Clinical Trial Simulation. <i>Blood</i> , 2016, 128, 3151-3151.	1.4	2
146	Cancer Microenvironment and Therapeutic Implications. , 2009, , .		2
147	Cancer Stem Cells: Historical Perspectives and Lessons from Leukemia. , 2011, , 3-11.		1
148	Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources. <i>Cancer</i> , 2014, 120, 1614-1616.	4.1	1
149	Response to Letter Regarding Article, "A Detailed Analysis of Bone Marrow From Patients with Ischemic Heart Disease and Left Ventricular Dysfunction: BM CD34, CD11b and Clonogenic Capacity as Biomarkers for Clinical Outcomes" <i>Circulation Research</i> , 2014, 115, e36-7.	4.5	1
150	Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes. <i>Leukemia Research</i> , 2020, 96, 106425.	0.8	1
151	Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect [®] MDS/AML Disease Registry. <i>Blood</i> , 2018, 132, 4731-4731.	1.4	1
152	Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options. <i>Blood</i> , 2018, 132, 5506-5506.	1.4	1
153	Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study. <i>Blood</i> , 2018, 132, 1540-1540.	1.4	1
154	A Novel Simulation Method for Mapping Dysregulated Pathways and Predicting Effective Therapeutics in the Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 5595-5595.	1.4	1
155	Gene Mutations in MDS Associating with Peripheral Blood Count Abnormalities. <i>Blood</i> , 2015, 126, 1685-1685.	1.4	1
156	A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study. <i>Blood</i> , 2016, 128, 1713-1713.	1.4	1
157	A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 4037-4037.	1.4	1
158	Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge.. <i>Blood</i> , 2009, 114, 246-246.	1.4	1
159	Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M. <i>Blood</i> , 2011, 118, 4301-4301.	1.4	1
160	Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort. <i>Blood</i> , 2018, 132, 1539-1539.	1.4	1
161	Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS. <i>Blood</i> , 2021, 138, 3415-3415.	1.4	1
162	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. <i>Frontiers in Oncology</i> , 2021, 11, 806243.	2.8	1

#	ARTICLE	IF	CITATIONS
163	Cancer, Stem Cells and the Neoplastic Niche. , 2009, , 63-78.		0
164	Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the ConnectA® MDS/AML Disease Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S343-S344.	0.4	0
165	Absolute Lymphocyte Count Recovery Following Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, S301-S302.	2.0	0
166	Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry. Cancer Causes and Control, 2021, 32, 199-202.	1.8	0
167	Implementation of Cancer Plans in the United States: A Review. Healthcare (Switzerland), 2021, 9, 291.	2.0	0
168	Following the Breadcrumbs of Palliative Care Financial Sustainability to Big Data. Journal of Palliative Medicine, 2021, 24, 649-650.	1.1	0
169	Incorporation of Bone Marrow Derived Cells in Colonic Adenoma.. Blood, 2004, 104, 674-674.	1.4	0
170	Blocking the SDF1/CXCR4 Axis Inhibits Marrow Derived Vasculogenesis in Cancer.. Blood, 2006, 108, 3942-3942.	1.4	0
171	Tumor Vasculogenesis Can Be Derived from the Hematopoietic Stem Cell.. Blood, 2006, 108, 1806-1806.	1.4	0
172	Marrow Contributes to Kidney Vasculogenesis in Humans.. Blood, 2006, 108, 3943-3943.	1.4	0
173	Human Myeloid Leukemia Xenotransplant Model Demonstrates Leukemia Blood Vessels from Both Human and Mouse Origin.. Blood, 2006, 108, 4269-4269.	1.4	0
174	Marrow Makes Thyroid but Not Adrenal Tissues in Humans.. Blood, 2006, 108, 1688-1688.	1.4	0
175	A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. Blood, 2009, 114, 1772-1772.	1.4	0
176	AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.. Blood, 2009, 114, 1031-1031.	1.4	0
177	A Keyword Search Strategy to Identify Missed Cases of Myelodysplastic Syndromes in Population-Based Cancer Registries.. Blood, 2009, 114, 4852-4852.	1.4	0
178	Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant. Blood, 2010, 116, 4748-4748.	1.4	0
179	High Rate of Uncaptured Myelodysplastic Syndrome Cases at the State Cancer Registry Level. Blood, 2010, 116, 1890-1890.	1.4	0
180	AML Depends on VEGFR1 and Not VEGFR2 for Proliferation and Protection From Chemotherapy,. Blood, 2011, 118, 3598-3598.	1.4	0

#	ARTICLE	IF	CITATIONS
181	The Jak2 Kinase Inhibitor, G6, Reduces the Mutant Burden and Reverses Marrow Fibrosis in a Mouse Model of Jak2-V617F Mediated PMF,. Blood, 2011, 118, 3858-3858.	1.4	0
182	Acute Myeloid Leukemia Cells Generate Leukemic Endothelial Cells with Leukemogenic Potential: Blood Vessels As Sanctuaries for Leukemia Relapse. Blood, 2011, 118, 241-241.	1.4	0
183	Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 4462-4462.	1.4	0
184	CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2011, 118, 4299-4299.	1.4	0
185	Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update. Blood, 2012, 120, 2023-2023.	1.4	0
186	Peripheral Blood CD34+ Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.. Blood, 2012, 120, 3074-3074.	1.4	0
187	Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton.. Blood, 2012, 120, 2183-2183.	1.4	0
188	A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 4335-4335.	1.4	0
189	Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First GCSF Apheresis. Blood, 2013, 122, 4520-4520.	1.4	0
190	Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows. Blood, 2013, 122, 1412-1412.	1.4	0
191	Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 1928-1928.	1.4	0
192	Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database. Blood, 2014, 124, 6008-6008.	1.4	0
193	A Novel Method of Using Molecular Profiling in Myelodysplastic Syndromes to Predict Patient-Specific Potential Therapeutics. Blood, 2014, 124, 5591-5591.	1.4	0
194	Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins. Blood, 2014, 124, 2315-2315.	1.4	0
195	Angiotensin II-induced Hypertension Impairs Hematopoietic Stem Cell Homing and Engraftment. FASEB Journal, 2015, 29, 670.5.	0.5	0
196	Effect of Melphalan 140 Mg/m2 Versus 200 Mg/m2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation. Blood, 2015, 126, 1988-1988.	1.4	0
197	A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy. Blood, 2015, 126, 3852-3852.	1.4	0
198	Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome. Blood, 2015, 126, 96-96.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes. Blood, 2015, 126, 3221-3221.	1.4	0
200	Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances. Blood, 2016, 128, 2099-2099.	1.4	0
201	Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma. Blood, 2016, 128, 5832-5832.	1.4	0
202	WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 1538-1538.	1.4	0
203	Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the ConnectA® MDS/AML Disease Registry. Blood, 2018, 132, 4736-4736.	1.4	0
204	AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow. Blood, 2018, 132, 4034-4034.	1.4	0
205	Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study. Blood, 2018, 132, 1541-1541.	1.4	0
206	Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study. Blood, 2018, 132, 3086-3086.	1.4	0
207	Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System. Blood, 2018, 132, 3087-3087.	1.4	0
208	Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics. Blood, 2018, 132, 3193-3193.	1.4	0
209	Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the ConnectA® MDS/AML Registry. Blood, 2019, 134, 4747-4747.	1.4	0
210	Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions. Blood, 2019, 134, 5418-5418.	1.4	0
211	Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial. Blood, 2021, 138, 1277-1277.	1.4	0
212	Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial. Blood, 2021, 138, 875-875.	1.4	0
213	Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Blood, 2021, 138, 3416-3416.	1.4	0
214	Direct Intravital Imaging of the Bone Marrow and Splenic Hematopoietic Niches in Individual Mice to Define the Early Engraftment Kinetics Following HSC-Transplant. Blood, 2021, 138, 3812-3812.	1.4	0
215	Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial. Blood, 2021, 138, 1279-1279.	1.4	0